Structure Therapeutics In... (GPCR)
Structure Therapeutics Inc. (GPCR) Stock Price, Analysis & Data
| Geld | 36.54 |
| Marktkapitalisierung | 3.78 Mrd |
| Umsatz (TTM) | n/a |
| Nettogewinn (TTM) | -214.84 Mio |
| Beta | -1.51 |
| EPS (ttm) | -3.03 |
| KGV (TTM) | n/a |
| Forward-KGV | -25.04 |
| KBV (TTM) | 2.47 |
| KUV (TTM) | n/a |
| Earnings Date | Nov 5, 2026 |
| Brief | 64 |
| Volumen | 66,112 |
| Ø Vol. (20D) | 714,545 |
| Eröffnung | 54.61 |
| Vortagesschluss | 54.70 |
| Tagesspanne | 53.51 - 54.79 |
| 52-Wk Range | 18.26 - 94.90 |
| Analyst | n/a |
| Kursziel | n/a |
| Dividenden | n/a |
| Ex-Dividenden-Datum | n/a |
Über GPCR
Structure Therapeutics Inc., a clinical stage global biopharmaceutical company, develops and delivers novel oral small molecule therapeutics to treat various chronic diseases with unmet medical needs in the United States. Its lead product candidate is GSBR-1290, an oral and biased small molecule agonist of glucagon-like-peptide-1 receptor, which is in two phase 2 clinical trials for the treatment of obesity, overweight, and related conditions. Th...
Finanzielle Entwicklung
Im Jahr 2025 betrug der Umsatz von Structure Therapeutics 0, ein Anstieg von undefined% im Vergleich zum Vorjahr (0). Der Gewinn lag bei -141.2 Mio, ein Anstieg von 15.24 %.
FinanzberichteGewinnüberraschung
Analysten erwarten einen Umsatz von ... Upgrade
vor 2 Monaten · Insider Monkey
H.C. Wainwright Reiterates Buy Rating for Structure Therapeutics (GPCR)Structure Therapeutics Inc. (NASDAQ:GPCR) is one of the 10 best mid-cap stocks that could double your money. On June 11, H.C. Wainwright reduced its price target on Structure Therapeutics Inc. (NASDAQ...
